{"id":"NCT02173158","sponsor":"Aegerion Pharmaceuticals, Inc.","briefTitle":"Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy","officialTitle":"A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-02","primaryCompletion":"2015-04-03","completion":"2015-12-17","firstPosted":"2014-06-24","resultsPosted":"2018-10-10","lastUpdate":"2018-10-10"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Familial Hypercholesterolemia - Homozygous"],"interventions":[{"type":"DRUG","name":"lomitapide","otherNames":["Juxtapid, Lojuxta"]}],"arms":[{"label":"lomitapide","type":"EXPERIMENTAL"}],"summary":"Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy.","primaryOutcome":{"measure":"Percent Change in LDL-C","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Lomitapide","deltaMin":-42.2,"sd":18.16}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Diarrhoea","Nasopharyngitis","Anaemia","Liver function test abnormal","Nausea"]}}